|
|
|
A Single Place.
A World of Care.
Determining Genetic Signature Of Lung Tumors Can Help Guide Treatment
A new study in the May 20 Journal of Clinical Oncology led by Massachusetts General Hospital Cancer Center investigators found that upfront gefitinib (Iressa®) treatment considerably improved the outcomes for non-small-cell-lung-cancer (NSCLC). "This is a pivotal clinical trial that demonstrates the power of personalized medicine in lung cancer treatment,” says Lecia Sequist, MD, MPH, of the Cancer Center, who led the study. “It is an exciting glimpse into what we hope is the future of cancer care. Instead of a ‘one size fits all’ therapy, we are moving towards finding the best treatment for each patient.” Read More >
Microchip-based Device Can Detect Rare Tumor Cells in Bloodstream
A team of investigators from the Massachusetts General Hospital (MGH) Biomicroelectromechanical Systems (BioMEMS) Resource Center and the MGH Cancer Center have developed a microchip-based device that can isolate, enumerate and analyze circulating tumor cells (CTCs) from a blood sample.
Read More >
Upcoming Events
Avon Walk for Breast Cancer
May 20- 21, 2008
Read More >
theonehundred
June 5, 2008
Read More >
Brian D. Silber Memorial Golf Tournament
July 16, 2008
Read More >
All Events >
|
|
Cancer Center RN Receives Award from ACS
Karleen Habin, RN, Administrator, Breast Cancer Research Program, is one of eight national receipients of the Lane Adams Quality of Life Award.  In her role as a patient advocate, she created the first-ever Breast Cancer Resource Guide of MA, which was distributed free of charge to a multitude of patients, families, and organizations.
The Breast Cancer Research Program is a nationally and internationally recognized breast cancer clinical research program at the Massachusetts General Hospital Cancer Center.
|
